Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents

Journal of Cardiology

Volumn 55, Issue 3, 2010, Pages 362-369

  Uchida, Yoshie ^a   Mori, Fumiaki ^a   Ogawa, Hiroshi ^a   Takagi, Atsushi ^a   Hagiwara, Nobuhisa ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Antiplatelet; Cardiovascular disease; Systemic embolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; TICLOPIDINE; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART VENTRICLE CONTRACTION; HEART VENTRICLE FUNCTION; HEMORRHAGIC SHOCK; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRESCRIPTION; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; STENT THROMBOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY DISEASES; MALE; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PYRIDINES; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION; WARFARIN;

EID: 77952239381     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2009.12.014     Document Type: Article

References (26)

1. Popma J.J., Berger P., Ohman E.M., Harrington R.A., Grines C., and Weitz J.I. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 576S-599S
2. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., Morrison D.A., O'Neill W.W., Schaff H.V., Whitlow P.L., Williams D.O., Antman E.M., Adams C.D., Anderson J.L., Faxon D.P., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
3. Silber S., Albertsson P., Aviles F.F., Camici P.G., Colombo A., Hamm C., Jørgensen E., Marco J., Nordrehaug J.E., Ruzyllo W., Urban P., Stone G.W., and Wijns W. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26 (2005) 804-847
4. Ong A.T., Hoye A., Aoki J., van Mieghem C.A., Rodriguez Granillo G.A., Sonnenschein K., Regar E., McFadden E.P., Sianos G., van der Giessen W.J., de Jaegere P.P., de Feyter P., van Domburg R.T., and Serruys P.W. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 (2005) 947-953
5. Kimura T., Morimoto T., Nakagawa Y., Tamura T., Kadota K., Yasumoto H., Nishikawa H., Hiasa Y., Muramatsu T., Meguro T., Inoue N., Honda H., Hayashi Y., Miyazaki S., Oshima S., et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119 (2009) 987-995
6. Byrne R.A., Schulz S., Mehilli J., Iijima R., Massberg S., Neumann F.J., ten Berg J.M., Schömig A., and Kastrati A. Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And Efficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 157 (2009) 620-4e2
7. Lip G.Y., and Boos C.J. Antithrombotic treatment in atrial fibrillation. Heart 92 (2006) 155-161
8. Toyoda K., Yasaka M., Iwade K., Nagata K., Koretsune Y., Sakamoto T., Uchiyama S., Gotoh J., Nagao T., Yamamoto M., Takahashi J.C., and Minematsu K. Bleeding with Antithrombotic Therapy (BAT) Study Group. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 39 (2008) 1740-1745
9. Orford J.L., Fasseas P., Melby S., Burger K., Steinhubl S.R., Holmes D.R., and Berger P.B. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 147 (2004) 463-467
10. Buresly K., Eisenberg M.J., Zhang X., and Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165 (2005) 784-789
11. Rubboli A., Colletta M., Sangiorgio P., and Di Pasquale G. Antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Ital Heart J 5 (2004) 919-925
12. Levey A.S., Coresh J., Greene T., Stevens L.A., Zhang Y.L., Hendriksen S., Kusek J.W., Van Lente F., and Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006) 247-254
13. Bovill E.G., Terrin M.L., Stump D.C., Berke A.D., Frederick M., Collen D., Feit F., Gore J.M., Hillis L.D., Lambrew C.T., Leiboff R., Mann K.G., Markis J.E., Pratt C.M., Sharkey S.W., Sopko G., Tracy R.P., and Chesebro J.H. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 115 (1991) 256-265
14. Kamath S., Blann A.D., Chin B.S., and Lip G.Y. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 40 (2002) 484-490
15. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S., Chrolavicius S., Pfeffer M., Hohnloser S., and Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
16. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., and Kuntz R.E. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998) 1665-1671
17. Bertrand M.E., Legrand V., Boland J., Fleck E., Bonnier J., Emmanuelson H., Vrolix M., Missault L., Chierchia S., Casaccia M., Niccoli L., Oto A., White C., Webb-Peploe M., Van Belle E., et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98 (1998) 1597-1603
18. Rubboli A., Milandri M., Castelvetri C., and Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 104 (2005) 101-106
19. Karjalainen P.P., Porela P., Ylitalo A., Vikman S., Nyman K., Vaittinen M.A., Airaksinen T.J., Niemelä M., Vahlberg T., and Airaksinen K.E. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28 (2007) 726-732
20. Testa L., Zoccai G.B., Porto I., Trotta G., Agostoni P., Andreotti F., and Crea F. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. Am J Cardiol 99 (2007) 1637-1642
21. Khurram Z., Chou E., Minutello R., Bergman G., Parikh M., Naidu S., Wong S.C., and Hong M.K. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 18 (2006) 162-164
22. Rothberg M.B., Celestin C., Fiore L.D., Lawler E., and Cook J.R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143 (2005) 241-250
23. Ruiz-Nodar J.M., Marin F., Hurtado J.A., Valencia J., Pinar E., Pineda J., Gimeno J.R., Sogorb F., Valdés M., and Lip G.Y. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51 (2008) 818-825
24. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., and Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 (2006) 1260-1264
25. Nusca A., Lipinski M.J., Varma A., Appleton D.L., Goudreau E., Cowley M.J., Wittkamp M.J., Di Sciascio G., Vetrovec G.W., and Abbate A. Safety of drug-eluting stents in patients with left ventricular dysfunction undergoing percutaneous coronary intervention. Am J Cardiol 102 (2008) 679-682
26. Aggarwal A., Dai D., Rumsfeld J.S., Klein L.W., and Roe M.T. Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention. Am J Cardiol 101 (2008) 1413-1417